Modulating CD27 signaling to treat cancer

Riether, Carsten; Schürch, Christian; Ochsenbein, Adrian (2012). Modulating CD27 signaling to treat cancer. Oncoimmunology, 1(9), pp. 1604-1606. Austin, Tex.: Landes Bioscience 10.4161/onci.21425

[img] Text
onci%2E21425.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.
Download (401kB)

CD27 signaling can either improve T-cell function or lead to T-cell dysfunction, depending on the duration and conditions of receptor ligation. Recent studies have shown that modulating the CD70-CD27 interaction is an attractive strategy to treat solid tumors and also to directly target leukemia stem cells.

Item Type:

 Journal Article (Original Article)

Division/Institute:

 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
04 Faculty of Medicine > Service Sector > Institute of Pathology > Autopsy
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

 Riether, Carsten, Schürch, Christian, Ochsenbein, Adrian

Subjects:

 600 Technology > 610 Medicine & health

ISSN:

 2162-4011

Publisher:

 Landes Bioscience

Language:

 English

Submitter:

 Factscience Import

Date Deposited:

 04 Oct 2013 14:33

Last Modified:

 05 Dec 2022 14:10

Publisher DOI:

 10.4161/onci.21425

PubMed ID:

 23264908

Web of Science ID:

 000316281700018

BORIS DOI:

 10.7892/boris.12776

URI:

 https://boris.unibe.ch/id/eprint/12776 (FactScience: 219247)

Actions (login required)

Edit item Edit item
Provide Feedback